EMILIO
ESTEBAN GONZALEZ
Profesor Titular de Universidad
Publicacions (125) Publicacions de EMILIO ESTEBAN GONZALEZ
2024
-
Blood tumor mutational burden and response to pembrolizumab plus chemotherapy in non–small cell lung cancer: KEYNOTE-782
Lung Cancer, Vol. 190
-
Concealed Inherited Cardiomyopathies Detected in Cardio-Oncology Screening
Journal of Clinical Medicine, Vol. 13, Núm. 1
-
EGFR exon 18 delE709_T710insD mutated stage IV non-small cell lung cancer treated with osimertinib: a case report
Anti-Cancer Drugs, Vol. 35, Núm. 7, pp. 638-640
-
Marital Status, Living Arrangement, and Survival among Individuals with Advanced Prostate Cancer in the International Registry for Men with Advanced Prostate Cancer
Cancer Epidemiology Biomarkers and Prevention, Vol. 33, Núm. 3, pp. 419-425
-
Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer
Clinical Cancer Research, Vol. 30, Núm. 14, pp. 3036-3049
-
“Inherited cardiovascular disease mindset” can identify concealed inherited conditions at cardio-oncology evaluation: An opportunistic screening.
International Journal of Cardiology, Vol. 401
2023
-
Impact of systemic cancer treatment on quality of life and mental well-being: a comparative analysis of patients with localized and advanced cancer
Clinical and Translational Oncology, Vol. 25, Núm. 12, pp. 3492-3500
-
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes from the Phase 3 KEYNOTE-189 Study
Journal of Clinical Oncology, Vol. 41, Núm. 11, pp. 1992-1998
-
Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial
The Lancet Oncology, Vol. 24, Núm. 11, pp. 1252-1265
2022
-
A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial
European Journal of Cancer, Vol. 175, pp. 110-119
-
Bilateral diffuse uveal melanocytic proliferation (BDUMP) as ocular toxicity from durvalumab in advanced renal carcinoma
European Journal of Cancer
2021
-
Circulating levels of the interferon-γ-regulated chemokines cxcl10/cxcl11, il-6 and hgf predict outcome in metastatic renal cell carcinoma patients treated with antiangiogenic therapy
Cancers, Vol. 13, Núm. 11
-
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189
Annals of Oncology, Vol. 32, Núm. 7, pp. 881-895
2020
-
ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort
Revista Espanola de Patologia, Vol. 53, Núm. 3, pp. 140-148
-
PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma
International Journal of Cancer, Vol. 146, Núm. 5, pp. 1435-1444
-
Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
The Lancet Oncology, Vol. 21, Núm. 3, pp. 387-397
-
Randomised Phase II study comparing alternating cycles of sunitinib and everolimus vs standard sequential administration in first-line metastatic renal carcinoma (SUNRISES study)
BJU International, Vol. 126, Núm. 5, pp. 559-567
-
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 14, pp. 1505-1517
2019
-
Deep sequencing reveals microRNAs predictive of antiangiogenic drug response
JCI Insight, Vol. 1, Núm. 10
-
Observational Prospective Study to Determine the Evolution of the Symptomatic Profile of Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients and Its Relation to the Control of the Disease
Advances in Therapy, Vol. 36, Núm. 6, pp. 1497-1508